Full text is available at the source.
Abstract
Patients with obesity class IV and V may benefit substantially from bariatric surgery.
- A significant number of patients do not complete the preoperative pathway for bariatric surgery.
- The impact of system-level barriers on the progression to surgery is not well understood.
- The role of glucagon-like peptide-1 receptor agonist therapy in non-progression remains unclear.
- Understanding these factors is essential, especially in community settings.
Simplified